Navigation Links
CSL Therapy That Mimics “Good” Cholesterol May Reduce,Plaque Volume in Coronary Arteries

o baseline, the reduction for patients infused with CSL-111 was statistically significant (p< 0.001), but this was not the case in the placebo group. Other assessments of the plaque, such as characterization indexes or changes in plaque that are different than volume measurements, on IVUS and coronary score on QCA, were significantly different between CSL-111 and placebo. Interestingly, the difference in coronary score between patients that had 4 weeks of CSL-111 and those given placebo was similar to those observed after two years of statin treatment (compared with no statin).

“Overall, these results strongly suggest that CSL-111 is biologically active, and that short term infusions of CSL-111 result in a rapid, favourable effect on coronary atherosclerotic plaque,” said Dr. Tardif, Principal Investigator, Montreal Heart Institute. “These data strongly support the conduct of further clinical studies to assess whether CSL-111 will provide a clinical benefit to patients with ACS.”

“This study is a significant step in our development of CSL-111,” said Dr. Andrew Cuthbertson. “CSL recognizes the value that CSL-111 may provide in preventing further cardiovascular events in patients with ACS. We are committed to exploring the full therapeutic potential of this treatment and will consult with international experts to evaluate next steps.”

ACS is the term used to describe unstable angina and myocardial infarction (heart attack). It is estimated to be responsible for up to 600,000 admissions to hospital per year in the US. Despite improvements in management over many years, ten to fifteen percent of patients still experience a serious cardiovascular problem in the 12 months following an episode of ACS.

CSL-111 is a patented biologic product, consisting of apolipoprotein A-I purified from human plasma that is reconstituted to form a particle that ch
'"/>




Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
(Date:7/11/2014)... 11, 2014 When the mercury rises, heat ... driving engine, the heart, takes on a heavier load in ... July 2014 issue of the Harvard Men's Health Watch ... requires no more than knowing their limits and drinking enough ... going to be more sensitive to the heat," says Dr. ...
(Date:7/11/2014)... Angeles, CA (PRWEB) July 11, 2014 ... Sands today announces that he uses mini and full ... treatments offer the defining feature that distinguishes dental implants ... teeth in addition to the crowns. This alone prevents ... implants also offer advantages related to comfort, appearance ...
(Date:7/11/2014)... -- A new study challenges the widely held belief that ... Researchers analyzed more than 50 studies that examined drinking ... They found that those with a form of a gene ... The gene affects how a person,s body breaks down alcohol, ... Having this variant has been shown to lead to lower ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cancer researchers ... have a significant impact on how patients respond to ... for mesothelioma. Surviving Mesothelioma has the full story. ... , Researchers at the University of Ljubljana and the ... pemetrexed for different types of polymorphisms. They found ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Anterior Cruciate ... year, but the type of material used to create ... in the game, say researchers presenting their work today ... of Sports Medicine ( AOSSM ). , ... population, allografts (tissue harvested from a donor) fail more ...
Breaking Medicine News(10 mins):Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:A Little Alcohol May Not Be Good for Your Heart After All 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... Hello Kitty, the moon-faced cartoon cat turned global icon of ... yen (32,000 dollars) for the ultimate pampered pooch . ... and a cushion bearing Hello Kitty's face, will be put ... Sanrio Co. said. ,Sanrio designer Ikuko Shimizu launched ...
... high-risk of having a heart attack are unclear about when ... an ambulance , argue a group of heart specialists in ... who die from coronary heart disease have had previous heart ... Foundation shows that 40% of the general population would not ...
... new score for predicting the risk of heart disease gives ... at risk of developing the disease and which adults are ... study published on bmj.com today, estimates that in the general ... million adults under the age of 75 in Britain at ...
... number of studies have suggested that regular exercise reduces inflammation ... other diseases, such as diabetes its still not clear ... link exists, the nature of the relationship is by no ... and community health researchers at the University of Illinois provides ...
... a medical device company founded in 2004 to bring ... surgical markets, announced that vascular surgeons at the ... clinically use their novel high performance vascular sealant, ArterX(TM). ... a 74 year old man suffering from vascular insufficiency ...
... has constituted rapid response teams to combat diseases of all ... teams have been formed to combat both contagious and non-contagious ... (IDSP)," Madhya Pradesh health minister Ajay Vishnoi told IANS. ... 2004 with an objective to compile survey work and immediate ...
Cached Medicine News:Health News:High-risk Patients Need Better Guidance on What is and Isnt a Heart Attack 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 3Health News:Exercise Reduces Inflammation 2Health News:Exercise Reduces Inflammation 3Health News:Exercise Reduces Inflammation 4Health News:Tenaxis Medical Inc. Announces First Human Use of Vascular Sealant 2
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
... Sprint Automated Urine Microscopy Analyzer (iQ200 Sprint) ... Series. The analyzer uses digital imaging and ... particles into 12 categories and quantitatively report ... time used to prepare and interpret urine ...
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
Medicine Products: